以綜合化學藥物CHOP治療非何杰金氏淋巴瘤之評估

自民國71年1月至75年6月間，三軍總醫院血液科使用綜合化學藥物CHOP（cyclophosphamide，adriamycin，vincristine，prednisolone）治療35位罹患非何杰金氏淋巴瘤（non-Hodgkin's lymphoma）之病患。患者年齡由18歲至79歲，平均年齡為41歲。男與女之比為4:1。其中兩位病理組織型態為好癒後者（good risk group）其餘均為壞癒後者（bad risk group）。得到完全緩解者有21位（60%），得到部份緩解者有13位（37.1%），治療失敗的有1位（2.9%）。白血球和血小板於治療後第9至16天降至最低點，於第19至27天恢復正常。病患中有8位因白血球降低而產生感染，但是只有1位因嚴重感染而死亡。血小板最低數目皆在50000/cumm以上，沒有出血併發症。本治療方式可在門診進行，對癒後較佳之淋巴瘤效果甚好，但對癒後較壞的患者，則必須採用更積極及更有效的藥物治療，始可奏效。Between January 1982 and June 1986, thirty-five patients with non-Hodgkin's lymphoma were treated with cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP). Two of these patients, belonged to the good risk group according to the pathological findings; the remainder belonged to the bad risk group. Twenty-one patients (60%) achieved complete remission. Median remission time was 23.4 months. Thirteen patients (37.1%) achieved partial remission. One patient (2.9%) failed to respond. Approximately at the 9th to 16th day after chemotherapy, the white blood count and platelet count dropped to nadir and returned to normal between the 19th to 27th day. Eight patients developed infection when the while count dropped. However, only one patient died of pneumonia. The nadir of platelet count for all patients was greater than 50000/cumm. No bleeding complication was noted. This regimen was effective and convenient. The toxicity was acceptable and tolerable.